Amiko’s Respiro platform receives CE Mark
LONDON – Amiko Digital Health Limited, a company that develops advanced medication sensor technologies and artificial intelligence-powered digital health tools, has received CE Mark for use of the Respiro platform with Teva’s Spiromax inhaler, Chiesi’s Nexthaler inhaler and GlaxoSmithKline’s Ellipta inhaler. “Receiving the CE Mark is a significant milestone toward the global commercialization of our connected inhaler technology,” said Federica Iovine, director of regulatory affairs at Amiko, in a statement. Respiro offers advanced inhaler sensors and connected health tools, enabling real-time monitoring of medication use and patient health. Combined with inhalers for asthma, chronic obstructive pulmonary disease and cystic fibrosis, the sensors automatically capture data on the patient’s inhalation profiles to monitor when and how well patients use their medication.
FDA approves seizure monitor watch
CAMBRIDGE, Mass. – Empatica Inc. has received clearance from the U.S. Food and Drug Administration for Embrace, an artificial intelligence-powered smart watch that monitors for grand mal seizures in patients with epilepsy. “The FDA approval of the Embrace device to detect major convulsive seizures represents a major milestone in the care of epilepsy patients,” said Orrin Devinsky, director of the Comprehensive Epilepsy Center at New York University, in a statement. “The scientific evidence strongly supports that prompt attention during or shortly after convulsive seizures can be life-saving in many cases.”
In a recent multi-site clinical study, 135 patients diagnosed with epilepsy were admitted to top level IV epilepsy monitoring units for continuous monitoring with video-EEG, while simultaneously wearing the device and its algorithm was shown to detect 100% of the seizures. Embrace measures multiple indicators of a seizure using of electrodermal activity, a signal used by stress researchers to quantify physiological changes related to sympathetic nervous system activity, also known as the “fight or flight” response. Empatica Inc. is a Massachusetts Institute of Technology Media Lab spin-off, with offices in Cambridge, Mass. and Milan, Italy.
Researchers develop webcam that measures heartbeat
LOGAN, Utah – Researchers at Utah State University have developed a webcam that can measure a person’s heartbeat.
Professor of electrical engineering Jake Gunther, a professor of electrical engineering at USU, and Nate Ruben, Gunther’s former student, developed software that works with a video camera to record images in values of red, green and blue. The green channel provides information that makes heart rate estimation possible. “Hemoglobin in the blood has an absorption peak for green light,” said Gunther in a statement. “So when the heart pushes blood into arteries near the skin, more green light is absorbed and less is reflected. This means we see fewer green values in the images from the camera.”
The system processes the color data and computes an average over regions of the image where skin is visible on the face, neck or arms. “The operation of our system is similar to a pulse oximeter,” said Ruben in a statement. “But instead of looking at the light transmitted through skin tissue, we’re looking at the light being reflected from it.”
Ascension Healthcare elevates Henderson
- LOUIS, Mo. – Ascension Healthcare, the healthcare delivery subsidiary of Ascension, has named Kristi Henderson vice president of patient access and care delivery transformation. Her new role will involve building a national approach and solution center for remote care coordination, central referral resources, transfer management, remote patient monitoring, call center services and appointment scheduling. “She understands the importance of using virtual medicine to enhance effective care models, with the overall goal of filling any gaps, adding innovative solutions and serving patients more efficiently,” said Karen Springer, president of healthcare operations at Ascension Healthcare, in a statement. Henderson is nationally recognized for successfully increasing access to high-quality, low-cost health care for thousands of patients through virtual care models, and has served as the vice president of virtual care and innovation for Ascension Texas since 2015. She joined Ascension from the University of Mississippi Medical Center, where she was chief telehealth and innovation officer, leading the development of a statewide telehealth program, which was recognized as a national model.
AXA Group acquires Maestro Health
CHICAGO – AXA Group has acquired employee health and benefits platform startup Maestro Health. AXA’s acquisition of Maestro Health and its all-in benefits platform, maestroEDGE, supports AXA’s payer-to-partner strategy in line with its ‘Ambition 2020’ corporate initiative,” said Guillaume Borie, chief innovation officer at AXA Group, in a statement. Maestro Health will maintain its identity, mission and team while operating as a wholly-owned subsidiary of AXA. “Not only is this the optimal step into the next phase of Maestro Health’s history, it’s also the ideal partnership to reinforce our all-in, continuum of care model—and ultimately transform health care as we know it today,” said Rob Butler, CEO and founder of Maestro Health, in a statement. With AXA, Maestro Health customers will see enhancements in their experience and access to leading product offerings. The company will also continue to focus on delivering new and improved solutions and services to the market, designed to further reduce health care costs and improve engagement for constituents across the entire continuum of care.
JDRF funds EOPatch wearable insulin pump for children
NEW YORK and SEOUL, South Korea – The Juvenile Diabetes Research Foundation is partnering with EOFlow Co., Ltd. to develop a wearable, disposable automated insulin delivery patch for people with Type 1 diabetes.
EOFlow recently received Korean Ministry of Food and Drug Safety approval on its wearable insulin pump system, the EOPatch, which incorporates a proprietary electroosmotic pumping technology that makes it small and light. The company will work with the JDRF to create a device suitable for children.
“Innovation in automated insulin delivery devices and artificial pancreas systems will help to significantly improve health and quality of life for people with T1D,” said Jaime Giraldo, a research scientist at the JDRF, in a statement. “Next-generation wearable designs that are smaller and employ user-centric design will remove barriers that prevent some people, especially small children, from using these life-saving and life-changing glucose management devices.”
EOFlow will use funding from the partnership to develop and run clinical studies on the wearable device, which consists of an insulin pump and an integrated continuous glucose sensor that is run by a closed-loop program that autonomously regulates the blood glucose level with minimal user input.
The partnership marks the first time JDRF is granting funds to EOFlow for research and is also the first time that JDRF is funding a company in Korea.